Elsevier eBooks, Journal Year: 2023, Volume and Issue: unknown, P. 107 - 136
Published: Nov. 3, 2023
Language: Английский
Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(20)
Published: April 6, 2024
Abstract The development of functional nanoplatforms to improve the chemotherapy outcome and inhibit distal cancer cell metastasis remains an extreme challenge in management. In this work, a human‐derived PC‐3 membrane‐camouflaged chitosan‐polypyrrole nanogel (CH‐PPy NG) platform, which can be loaded with chemotherapeutic drug docetaxel (DTX) RANK siRNA for targeted gene silencing‐mediated inhibition late‐stage prostate mouse model, is reported. prepared NGs size 155.8 nm show good biocompatibility, pH‐responsive release profile, homologous targeting specificity cells, allowing efficient precise drug/gene co‐delivery. Through in‐vivo antitumor treatment xenografted tumor it shown that such CH‐PPy NG‐facilitated co‐delivery system allows effective slow down growth rate, effectively inhibits bone via downregulation RANK/RANKL signaling pathway. created CH‐Ppy may utilized as promising platform enhanced anti‐metastasis cancer.
Language: Английский
Citations
12
Cancer Informatics, Journal Year: 2025, Volume and Issue: 24
Published: Jan. 1, 2025
Objectives: Prostate cancer stem cells (CSCs) play an important role in cell survival, proliferation, metastasis, and recurrence; thus, removing CSCs is for complete removal. However, the mechanisms underlying CSC functions remain largely unknown, making it difficult to develop new anticancer drugs targeting CSCs. Herein, we aimed identify novel factors that regulate stemness predict prognosis. Methods: We reanalyzed 2 single-cell RNA sequencing data of prostate (PCa) tissues using Seurat. used gene set enrichment analysis (GSEA) estimate identified common upregulated genes between these datasets. To investigate whether its expression levels change over differentiation, performed a trajectory monocle 3. In addition, GSEA helped us understand how stemness. Finally, assess their clinical significance, Cancer Genome Atlas database evaluate impact on Results: The thioredoxin ( TXN), redox enzyme, was approximately 1.2 times higher than PCa P < 1 × 10 −10 ), TXN decreased differentiation. suggested intracellular signaling pathways, including MYC, may be involved regulation by TXN. Furthermore, correlated with poor prognosis (P .05) patients high Conclusions: Despite limited sample size our study need further vitro vivo experiments demonstrate functionally regulates CSCs, findings suggest serve as therapeutic target against Moreover, could useful marker predicting patients.
Language: Английский
Citations
1
OncoImmunology, Journal Year: 2024, Volume and Issue: 13(1)
Published: Aug. 21, 2024
The inflammatory tumor microenvironment (TME) is a key driver for tumor-promoting processes. Tumor-associated macrophages are one of the main immune cell types in TME and their increased density related to poor prognosis prostate cancer. Here, we investigated influence pro-inflammatory (M1) immunosuppressive (M2) on cancer lineage plasticity. Our findings reveal that M1 macrophage secreted factors upregulate genes stemness while downregulating associated with androgen response cells. expression stem (CSC) plasticity markers NANOG, KLF4, SOX2, OCT4, CD44 was stimulated by from macrophages. Moreover, AR its target gene PSA were observed be suppressed LNCaP cells treated Inhibition NFκB signaling using IKK16 inhibitor resulted downregulation CSC study highlights drive upregulating through pathway.
Language: Английский
Citations
6
Cancers, Journal Year: 2023, Volume and Issue: 15(5), P. 1621 - 1621
Published: March 6, 2023
Prostate cancer (PCa) is the second-most commonly diagnosed in men around world. It treated using a risk stratification approach accordance with National Comprehensive Cancer Network (NCCN) United States. The main treatment options for early PCa include external beam radiation therapy (EBRT), brachytherapy, radical prostatectomy, active surveillance, or combination approach. In those advanced disease, androgen deprivation (ADT) considered as first-line therapy. However, majority of cases eventually progress while receiving ADT, leading to castration-resistant prostate (CRPC). near inevitable progression CRPC has spurred recent development many novel medical treatments targeted therapies. this review, we outline current landscape stem-cell-targeted therapies PCa, summarize their mechanisms action, and discuss avenues future development.
Language: Английский
Citations
14
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 10910 - 10910
Published: June 30, 2023
Cancer remains a leading cause of death globally, and its complexity poses significant challenge to effective treatment. stem cells their markers have become key players in tumor growth progression. CD133, marker various cancer types, is an active research area as potential therapeutic target. This article explores the role CD133 treatment, beginning with overview statistics explanation markers. The rise discussed, including structure, functions, occurrence different types. Furthermore, covers target, focusing on gene therapy, immunotherapy, approaches affect expression. Nanoparticles such gold nanoparticles nanoliposomes are also discussed context CD133-targeted therapy. In conclusion, promising target for As this progresses, it hoped that therapies will offer new treatment options patients future.
Language: Английский
Citations
14
Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(3)
Published: March 26, 2024
Dysregulated activation of Wnt/β-catenin signaling pathway is a frequent or common event during advanced progression multiple cancers. With this activation, it enhances their tumorigenic growth and facilitates metastasis therapy resistance. Advances show that can play dual regulatory roles in the control cellular processes epithelial-mesenchymal transition (EMT) cancer stemness progression. Aberrant shown to be prostate also castration-resistant (CRPC). However, transcriptional regulators are still not well characterized. NURR1 (NR4A2) an orphan nuclear receptor plays important role development dopaminergic neurons. Previously, we have exhibits upregulation isolated stem-like cells (PCSCs) xenograft model CRPC. In study, further confirmed exhibited enhanced expression cell lines. Functional molecular analyses showed could act promote both vitro (cancer EMT) vivo oncogenic (metastasis castration resistance) via its direct transactivation CTNNB1 (β-catenin) β-catenin mediate pathway. Moreover, demonstrated activity modulated by small molecules, implicating potential therapeutic target for management.
Language: Английский
Citations
5
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(9), P. 7746 - 7746
Published: April 24, 2023
Cancer stem cells (CSCs) are a small and elusive subpopulation of self-renewing cancer with the remarkable ability to initiate, propagate, spread malignant disease. In past years, several authors have focused on possible role CSCs in PCa development progression. typically originate from luminal prostate cell. Three main pathways involved CSC development, including Wnt, Sonic Hedgehog, Notch signaling pathways. Studies observed an important for epithelial mesenchymal transition this process as well some specific miRNA. These studies led targeting these improve management represent actual promising field research.
Language: Английский
Citations
13
Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13
Published: March 9, 2023
The development of new therapeutic strategies is on the increase for prostate cancer stem cells, owing to current standardized therapies cancer, including chemotherapy, androgen deprivation therapy (ADT), radiotherapy, and surgery, often failing because tumor relapse ability. Ultimately, develops into advanced castration-resistant (CRPC), which becomes an irreversible systemic disease. Hence, early identification intracellular components molecular networks that promote crucial disease management intervention. One potential methods aggressive target cells (PCSCs), appear be a primary focal point metastasis recurrence are resistant therapies. PCSCs have also been documented play major role in regulating tumorigenesis, sphere formation, ability with their stemness features. Therefore, review highlights origin anti-androgen resistance, as well stemness-related signaling pathways. In addition, focuses targeting helping prevent initiation progression, such microRNAs (miRNAs), nanotechnology, immunotherapy, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene-editing system, photothermal ablation (PTA) therapy.
Language: Английский
Citations
12
Antibodies, Journal Year: 2025, Volume and Issue: 14(1), P. 5 - 5
Published: Jan. 9, 2025
Photoimmunotherapy (PIT) is an innovative approach for the targeted therapy of cancer. In PIT, photosensitizer dyes are conjugated to tumor-specific antibodies delivery into cancer cells. Upon irradiation with visible light, dye activated and induces cancer-specific cell death. present article, we describe PIT prostate (PC) as a therapeutic option treatment localized We silicon phthalocyanine WB692-CB2 recombinant cysteine-modified anti-CD44 anti-EpCAM via maleimide linker tested antibody conjugates on PC cells stem (PCSC)-like The showed specific binding high cytotoxicity against PCSC-like following red light. Combined both led enhanced cytotoxic effects. our can serve effective focal cancer, preserving gland minimizing side It be employed during radical prostatectomy (RP) treat residual tumor or lymph node metastases in areas where further surgical intervention not feasible. Utilizing multiple antigens expressed differentiated cells, such CD44 EpCAM, could method eradicate heterogeneous tumors. This reduce risk local recurrence after RP thus increase outcome patients.
Language: Английский
Citations
0
Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)
Published: March 26, 2025
Although immune checkpoint (IC) inhibition is a major treatment modality in cancer-immunotherapy, multiple cancers show low response. Our in-silico exploration by mining cancer datasets using R2, available clinical trial data, and Kaplan–Meier analysis from GEPIA depicted that unlike low-responder (LR) cancers, high-responder (HR) furnish higher IC expression, upon lowering may provide better prognosis. Contrastingly, pancreatic adenocarcinoma (PAAD) demonstrated high expression but immunotherapy-response. Infiltration scores TIMER2.0 revealed pro-tumor subsets cancer-associated fibroblasts (CAFs) while depicting lower anti-tumor PAAD as compared to HR lung (LUAD). Additionally, bioinformatic tool cBioportal showed lesser tumor mutational burden, mismatch repair deficiency greater percent of driver mutations TP53, KRAS CDKN2A PAAD, supporting its immunotherapy-resistance than LUAD. search for the 'key' immunotherapy response-deciding factor(s) stem cells (CSCs), known contributors therapy-resistance immuno-evasion, be positively correlated with above-mentioned mutations, CAF subsets; furnished CSC genes UMAP/tSNE analyses signature pro-cancer cells, negatively cytotoxic-T PAAD. study explains immunotherapy-response IC-expressing wherein plays pivotal role. Further portrayed correlation CSCs other LR too, substantiating need personalized evaluation targeting successful outcomes.
Language: Английский
Citations
0